Cardiac failure (CF) and sudden cardiac death (SCD) stand out as two of the main causes of death in patients with aortic stenosis. Although transcatheter aortic valve intervention has shown higher survival, these two continue to be the main conditions leading to patient death at followup. In its early days, TAVR also showed benefits, but…
Latest Developments in Tricuspid Regurgitation
The natural history of tricuspid regurgitation is associated to hospitalization for cardiac failure and mortality. This is why the AHA/ACC guidelines recommend surgery when the tricuspid fails during left valve surgical repair, because its slow progression is associated with high mortality (35%). Many of these patients are high risk and percutaneous intervention has surged as…
A Simple Score for Mortality and Cardiac Failure after Edge-to-Edge with MitraClip
Mitral regurgitation (MR) is the most frequent type of valve heart disease, and the COAPT has shown that edge-to-edge with guideline directed medical treatment (GDMT) at maximal tolerated dose (MTD) is superior to medical treatment alone. However, we did not have a score to predict patient evolution when treated with this strategy. Researchers analyzed the…
ACC 2022 | IVVE
This randomized study aimed at assessing the flu vaccine vs placebo in patients with cardiac failure. It included 5129 patients with cardiac failure randomized to receiving the flu vaccine annually for 3 years vs placebo. Primary end point included cardiovascular death, non-fatal AMI, and stroke. There were no significant differences between both groups. However, pneumonia…
ACC 2022 | PROMPT-HF
Patients with cardiac failure with reduced ejection fraction (HFrEF) are sub treated when you look at guideline-directed medical therapy (GDMT). The aim of this study was to assess if, using an electronic registry, we can alert treating physicians and optimize medical treatment. 100 healthcare professionals (doctors, nurses, etc) were randomized to receiving and alert…
08/03 | LATAM Network of Interventional Women: 4 Simultaneous Educational Activities!
SOLACI and the Latin American Interventional Women Group (Grupo MIL) continue to promote continuing medical education, in this case with four simultaneous activities organized with Medtronic and aimed at female interventional specialists. In this one-of-a-kind session, participants will have the opportunity to discuss clinical data and procedural techniques with experts. The event will be held on…
Empagliflozin: Better Quality of Life for Patients with Cardiac Failure and Preserved Ejection Fraction
Empagliflozin has shown early and sustained improved quality of life (at least for a year) in patients with cardiac failure and preserved function. Patients with cardiac failure and preserved ejection fraction present a deteriorated quality of life. The EMPEROR-Preserved assessed the efficacy of Empagliflozin in several baseline health status assessments. HRQoL was measured using the…
ACC 2021 | Sacubitril/Valsartan not Superior to Ramipril after AMI
The combination sacubitril/valsartan following high-risk AMI did not reduce the risk of cardiac failure or cardiovascular risk in patients compared against ramipril. These data were provided by the PARADISE-MI presented today during the scientific sessions at ACC 2021. The combination sacubitril/valsartan had gathered prior evidence (basically from the PARADIGM-HF) for its superiority in terms of total…
Discount for SOLACI Members – V Heart Failure Review 2020
On December 7 thru 12 SOLACI is holding the 5th International Round of Conferences 2020 on “Heart Failure and Pulmonary Hypertension: Management of hear failure in times of polypharmacy and artificial devices”. The event will take place next week Monday thru Friday from 5 to 7 pm and Saturday 12 from 10 to 12 am…
AHA 2020 | EMPATROPISM: Empagliflozin in Non-Diabetics with Cardiac Failure
Empagliflozin improves cardiac function, exercise capacity and quality of life in non-diabetic patients with cardiac failure and deteriorated ejection fraction. These findings were presented during the scientific sessions at AHA 2020 and published simultaneously in JACC. EMPATROPISM outcomes are on the same line as other studies using sodium glucose 2 cotransporter inhibitors (SGLT2) which showed…
- 1
- 2